Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06732583 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 30, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Aug 2025 to Aug 2026
    • Start date changed from estimate of Feb 2025 to Nov 13, 2025
    • Study sites: 0 to 1
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups (Group A and B). In each treatment group, 18 participants will be randomly assigned to receive either the investigational vaccine (Dose A or Dose B of Ad5-105K) or a placebo in a ratio of 2:1. The distribution of participant's gender and age should be balanced in each group.
Trial Details
NCT Number NCT06732583
Lead Sponsor CanSino Biologics Inc.
Collaborators: PT Etana Biotechnologies Indonesia
Conditions
(from sponsor)		 Tuberculosis
Related terms Tuberculosis
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov